Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4111-4118

  Elkin, Michael ^a,b   Ariel, Ilana ^a   Miao, Hua Quan ^a,d   Nagler, Arnon ^a   Pines, Mark ^c   De Groot, Nathan ^b   Hochberg, Avraham ^b   Vlodavsky, Israel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c VOLCANI CENTER   (Israel)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOFUGINONE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINES; QUINAZOLINONES; STROMAL CELLS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033566986     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Yeo, T-K., and Dvorak, H. F. Tumor stroma. In: R. Colvin, A. Bhan, and R. McCluskey (eds.), Diagnostic Immunopathology, Ed. 2, pp. 685-697. New York: Raven Press, 1995.
2. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
3. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3: 65-71, 1992.
4. Vlodavsky, I., Bar-Shavit, R., Korner, G., and Fuks, Z. Extracellular matrix-bound growth factors, enzymes and plasma proteins. In: D. H. Rohrbach and R. Timpl (eds.), Basement Membranes: Cellular and Molecular Aspects, pp. 327-343. Orlando, FL: Academic Press, 1993.
5. Liotta, L. A., Rao, C. N., and Barsky, S. H. Tumor invasion and extracellular matrix. Lab. Invest., 49: 636-649, 1983.
6. Duffy, M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis, 10: 145-155, 1992.
7. Stetler-Stevenson, W. G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev., 9: 289-303, 1990.
8. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
9. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
10. Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Okawa, J., and Nakajima, M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56: 3196-3198, 1996.
11. Moses, M. A., Wiederschain, D., Loughlin, K. R., Zurakowski, D., Lamb, C. C., and Freeman, M. R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res., 58: 1395-1399, 1998.
12. Herron, G. S., Banda, M., Clarck, E. J., Gavrilovic, J., and Werb, Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. Expression of collagenase and stromeolysin activities is regulated by endogenous inhibitors. J. Biol. Chem., 261: 2814-2818, 1986.
13. Moses, M. A., Sudhalter, J., and Langer, R. Identification of an inhibitor of neovascularization from cartilage. Science (Washington DC), 248: 1408-1410, 1990.
14. Johnson, M. D., Kim, H-R. C., Chesler, L., Tsao-Wu, G., Bouck, N., and Polverini, P. J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell. Physiol., 160: 194-202, 1994.
15. Unemori, E. N., Bouhana, K. S., and Werb, Z. Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells. J. Biol. Chem., 265: 445-451, 1990.
16. Benelli, R., Adatia, R., Ensoli, B., Stetler-Stevenson, W. G., Santi, L., and Albini, A. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol. Res., 6: 251-257, 1994.
17. Takeshi, I., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.
18. Granot, I., Bartov, I., Davnik, I., Wax, E., Hurwitz, S., and Pines, M. Increased skin tearing in broilers and reduced collagen synthesis in vivo and in vitro in response to the coccidiostat halofuginone. Poult. Sci., 70: 1559-1563, 1991.
19. Granot, I., Halevy, O., Hurwitz, S., and Pines, M. Halofuginone: an inhibitor of collagen type I synthesis. Biochem. Biophys. Acta, 1156: 107-112, 1993.
20. Halevy, O., Nagler, A., Levi-Schaffer, F., Genina, O., and Pines, M. Inhibition of collagenase type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem. Pharmacol., 52: 1057-1062, 1996.
21. Nagler, A., Miao, H-Q., Aingorn, E,. Pines, M., Genina, O., and Vlodavsky, I. Inhibition of collagen synthesis, smooth muscle cell proliferation and injury-induced intimal hyperplasia by halofuginone. Arterioscler. Thromb. Vasc. Biol., 17: 194-202, 1997.
22. Nagler, A., Katz, A., Aingorn, E., Miao, H-Q., Condiotti, R., Genina, O., Pines, M., and Vlodavsky, I. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int., 52: 1561-1569, 1997.
23. Elkin, M., Reich, R., Nagler, A., Aingorn, E., Pines, M., de-Groot, N., Hochberg, A., and Vlodavsky, I. Inhibition of matrix metalloproteinase-2 (MMP-2) expression and bladder carcinoma metastasis by halofuginone. Clinical Cancer Res., in press.
24. Hirose, M., Fukushima, S., Hananouchi, M., Shirai, T., Ogiso, T., Takahashi, M., and Ito, N. Different susceptibilities of the urinary bladder epithelium of animal species to three nitroso compounds. Gann, 67: 175-189, 1976.
25. Ohtani, M., Kakizoe, T., Nisio, Y., Sato, S., Sugimura, T., Fukushima, S., and Nijima, T. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res., 46: 2001-2004, 1986.
26. Elkin, M., Ayesh, S., Schneider, T., de-Groot, N., Hochberg, A., and Ariel, I. The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutil)nitrosamine. Carcinogenesis (Lond.), 19: 2095-2099, 1998.
27. Ariel, I., Lustig, O., Schneider, T., Pizov, G., Sappir, M., de-Groot, N., and Hochberg, A. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology, 45: 335-338, 1995.
28. Adriaenssens, E., Dumont, I., Lottin, S., Bolle, D., Lepretre, A., Delobelle, A., Bouali, F., Dugimom, T., Coll, J., and Curgy, J. J. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am. J. Pathol., 153: 1597-1607, 1998.
29. Cooper, M., Fischer, M., Komitowski, D., Shevelev, A., Schulze, E., Ariel, I., Tykocinski, M., Miron, S., Ilan, J., de-Groot, N., and Hochberg, A. Developmentally imprinted genes as markers for bladder tumor progression. J. Urol., 155: 2120-2127, 1996.
30. Nativ, O., Aronson, M., Medalia, O., Moldavsky, T., Sabo, E., Ringel, I., and Kravtsov, V. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int. J. Cancer, 70: 297-301, 1997.
31. Nativ, O., Medalia, O., Mor, Y., Shajrawi, I., Sabo, E., and Aronson, M. Treatment of experimental mouse bladder tumor by LPS-induced epithelial cell shedding. Br. J. Cancer, 74: 603-605, 1996.
32. Strom, S. C., and Michalopoulos, G. Collagen as a substrate for cell growth and differentiation. Methods Enzymol. 82: 544-555, 1982.
33. Elsdale, T., and Bard, J. Collagen substrata for studies on cell behavior. J. Cell Biol. 54: 626-637, 1972.
34. Nicosia, R. F., and Ottinetti, A. Growth of microvessels in serum-free matrix culture of rat aorta. Lab. Invest. 63: 115-122, 1990.
35. Pines, M., Knopov, V., Genina, O., Lavelin, I., and Nagler, A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol., 27: 391-398, 1997.
36. Nagler, A., Rivkind, A., Raphael, J., Levi-Schaffer, F., Genina, O., Lavelin, I., and Pines, M. Halofuginone - an inhibitor of collagen type I synthesis - prevents post-operative formation of abdominal adhesions. Ann. Surg. 227: 575-582, 1998.
37. Beier, R. C., Dutco, T. J., Buckley, S. A., Muldoon, M. T., Holtzappe, C. K., and Stanker, L. H. Detection of halofuginone residues in chicken liver tissue by HPLC and a monoclonal-based immunoassay. J. Agric. Food Chem. 46: 1049-1054, 1998.
38. Kinabo, L. D., and McKellar, Q. A. Pharmacokinetics of halofuginone in cattle. Br. Vet. J., 145: 546-551, 1989.
39. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., and Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Dev. Today, 1: 16-26, 1996.
40. Primrose, J., Bleiberg, H., Daniel, F., Johnson, P., Mansi, J., Neoptolemos, J., Seymour, M., and Van Belle, S. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann. Oncol. 7: 35, 1996.
41. Iruela-Arispe, M. L., Hasselaar, P., and Sage, H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab. Invest., 64: 174-186, 1991.
42. Fouser, L., Iruela-Arispe, L., Bornstein, P., and Sage, E. H. Transcriptional activity of the α 1(I)-collagen promoter is correlated with the formation of capillary-like structures by endothelial cells in vitro. J. Biol. Chem., 266: 18345-18351, 1991.
43. Jackson, C. J., and Jenkins, K. L. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp. Cell Res., 192: 319-323, 1991.
44. Kim, D-K., Zang, L., Dzau, V., and Pratt, R. H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury. J. Clin. Invest. 93: 355-360, 1994.
45. Han, D. K. H., Khaing, Z., Pollock, R. A., Haudenschild, C. C., and Liau, G. H19, a marker of developmental transition, is reexpressed in human atherosclerotic plaques and is regulated by the insulin family of growth factors in cultured rabbit smooth muscle cells. J. Clin. Invest., 97: 1276-1285, 1996.
46. Pines, M., and Nagler, A. Halofuginone: a novel anti-fibrotic therapy. Gen. Pharmacol., 30: 445-450, 1998.